Brightgene Bio Medical Stock Cash Per Share

Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.

In accordance with the recently published financial statements, BrightGene Bio Medical has a Cash Per Share of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The cash per share for all China stocks is 100.0% higher than that of the company.

The Macroaxis Fundamental Analysis modules help investors analyze BrightGene Bio Medical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BrightGene Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BrightGene Bio Medical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

BrightGene Bio financial ratios help investors to determine whether BrightGene Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BrightGene with respect to the benefits of owning BrightGene Bio security.